 |
| Kåre Schultz |
So far, 2014 hasn't been the best year for Denmark's Novo Nordisk ($NVO). The perennially fast-growing drugmaker saw sales growth slip into the single digits for the first quarter. But the company believes its 2014 performance is just a temporary blip. Kåre Schultz, Novo's deputy CEO, predicts the company's annual revenues--about $15.3 billion last year--will double within the next decade. Report